ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...

Bio-Reference Laboratories, Inc. has announced that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the ...

- GenPath's growth stems from its ability to provide proprietary and highly differentiated tests in addition to comprehensive cancer laboratory tests in-house. GenPath provides complete cancer ...

GenPath Pharmaceuticals Inc., Cambridge, Mass., raised $42.7 million in series B funding. Flagship Ventures led the round, which included Highland Capital Partners, Oxford Biosciences, existing ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognized GenPath Diagnostics, a business unit of BioReference Laboratories, Inc ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (“BRLI”) (NASDAQ: BRLI) announced today that it has completed an equity investment in InCellDx, Inc. (“InCellDx”), a privately ...

Cambridge-based GenPath Pharmaceuticals Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year ...

Kenneth Weg, former vice chairman of Bristol-Myers Squibb, first heard the details about a technology to prioritize the best drug targets about a year ago. Raju Kucherlapati, a fellow member of the ...